Background
Methods
Patients
Evaluation of therapy responses
Enzyme linked immunosorbent assay (ELISA)
Statistical analysis
Results
Patients’ characteristics
Variables | SCLC patients | Healthy controls | P |
---|---|---|---|
Number of subject | 96 | 60 | |
Median (range) | 55 (36–75) | 56 (38–74) | 0.618 |
Male/Female | 66/30 | 40/20 | 0.786 |
Smoking history | |||
Ever smoker | 58 | 32 | 0.384 |
Never smoker | 38 | 28 | |
Performance status | |||
0–1 | 56 | ||
2–3 | 40 | ||
Disease stage | |||
Limited | 28 | ||
Extended | 58 | ||
Tumor size (cm) | |||
≥ 3 | 76 | ||
< 3 | 20 | ||
Lymph node metastasis | |||
N0 | 26 | ||
N1–3 | 70 | ||
Chemotherapy | |||
EP | 80 | ||
EC | 16 | ||
Radiotherapy sequence | |||
Concurrent | 43 | ||
After-chemotherapy | 40 | ||
None | 13 | ||
Responses | |||
CR + PR | 78 | ||
SD + PD | 18 |
Serum OPN levels in SCLC patients and healthy controls
The relationship between pre-treatment OPN levels and clinicopathological characteristics
Characteristics | Number | OPN level (ng/ml) | P |
---|---|---|---|
Age, yr | 0.954 | ||
≥ 60 | 54 | 73.78 ± 16.55 | |
< 60 | 42 | 73.43 ± 17.90 | |
Gender | 0.317 | ||
Male | 66 | 75.38 ± 16.44 | |
Female | 30 | 68.38 ± 18.19 | |
Smoking history | 0.077 | ||
Ever smoker | 58 | 68.32 ± 20.11 | |
Never smoker | 38 | 78.94 ± 11.13 | |
Performance status | 0.174 | ||
0–1 | 56 | 70.02 ± 17.39 | |
2–3 | 40 | 78.27 ± 15.55 | |
Disease stage | 0.012 | ||
Limited | 28 | 66.32 ± 19.64 | |
Extended | 58 | 80.94 ± 9.41 | |
Tumor size (cm) | 0.034 | ||
≥ 3 | 76 | 77.96 ± 14.31 | |
< 3 | 20 | 60.63 ± 18.18 | |
Lymph node metastasis | 0.037 | ||
N0 | 26 | 64.08 ± 21.85 | |
N1–3 | 70 | 79.40 ± 9.72 | |
Responses | 0.485 | ||
CR + PR | 78 | 71.15 ± 18.33 | |
SD + PD | 18 | 78.01 ± 13.74 |
Relationship between serum OPN levels and treatment response
Prognostic value of serum OPN levels for SCLC patients
Characteristics | Univariate | Multivariate | ||||
---|---|---|---|---|---|---|
HR | 95% CI | P | HR | 95% CI | P | |
Gender (Male vs. Female) | 3.563 | 0.496–25.582 | 0.206 | 2.264 | 0.382–13.404 | 0.368 |
Age (< 60 vs. ≥60) | 0.819 | 0.140–4.806 | 0.825 | 2.091 | 0.514–8.502 | 0.302 |
Disease stage (Limited vs. Extended) | 4.277 | 1.233–14.835 | 0.022 | 3.429 | 1.096–10.726 | 0.034 |
Lymph node metastasis (N0 vs. N1–3) | 0.585 | 0.157–2.182 | 0.424 | 2.358 | 0.606–9.181 | 0.216 |
PS (0–1 vs. 2–3) | 4.820 | 1.196–19.424 | 0.027 | 4.004 | 1.281–12.513 | 0.017 |
Smoking history (Ever vs. Never) | 1.719 | 0.551–5.365 | 0.351 | 0.649 | 0.218–1.933 | 0.438 |
Pre-OPN (Negative vs. Positive) | 2.662 | 0.908–7.807 | 0.075 | 0.305 | 0.091–1.106 | 0.053 |
After-OPN (Negative vs. Positive) | 4.936 | 1.793–13.586 | 0.002 | 6.114 | 1.661–22.510 | 0.006 |